Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHP Pondimin Limitations Discussed With FDA While Redux Was Under Review

Executive Summary

Wyeth-Ayerst informally discussed added limitations on Pondimin (fenfluramine) combination use while the Redux (dexfenfluramine) NDA was pending, former Wyeth-Ayerst Director-Medical Affairs Marc Deitch, MD, testified Sept. 7 during the ongoing diet-drug class action suit, Vadino v. American Home Products.

You may also be interested in...

AHP Redux Settlement Doubles Cash Payments For Use Of Drug Over 60 Days

Patients who used American Home Products' Redux or Pondimin for more than 60 days would be eligible to receive a cash payment of $6,000 if an echocardiogram shows heart valve regurgitation, while those who used the drugs for 60 days or less could receive $3,000, under a settlement proposed by AHP.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts